Related references
Note: Only part of the references are listed.Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor
N. A. Molfino et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2012)
Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
Maartje E. Visser et al.
EUROPEAN HEART JOURNAL (2012)
Obatoclax mesylate: pharmacology and potential for therapy of hematological neoplasms
Jamal Joudeh et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Cancer drug's survivin suppression called into question
David Holmes
NATURE MEDICINE (2012)
Outlook for the next 5 years in drug innovation
Roy Berggren et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Survivin in Solid Tumors: Rationale for Development of Inhibitors
David N. Church et al.
CURRENT ONCOLOGY REPORTS (2012)
RNA Interference Therapy in Lung Transplant Patients Infected with Respiratory Syncytial Virus
Martin R. Zamora et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer
Srikala S. Sridhar et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge
H. Imaoka et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2011)
Therapeutic Oligonucleotides: The Road Not Taken
Cy A. Stein et al.
CLINICAL CANCER RESEARCH (2011)
A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer
David S. Hong et al.
CLINICAL CANCER RESEARCH (2011)
Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c
Fred Saad et al.
CLINICAL CANCER RESEARCH (2011)
Therapeutic potential of antisense oligonucleotides for the management of dyslipidemia
Rosanne M. Crooke et al.
CLINICAL LIPIDOLOGY (2011)
Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
Fatima Akdim et al.
EUROPEAN HEART JOURNAL (2011)
Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis
Xin Ming
EXPERT OPINION ON DRUG DELIVERY (2011)
Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia
Pooja P. Advani et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
Sebahattin Cirak et al.
LANCET (2011)
The long march of antisense
Dan Jones
NATURE REVIEWS DRUG DISCOVERY (2011)
How were new medicines discovered?
David C. Swinney et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Targeting RNA to treat neuromuscular disease
Francesco Muntoni et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy
Nathalie M. Goemans et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients
Azeem Saleem et al.
THERANOSTICS (2011)
RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
C. Frank Bennett et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2010)
Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer
Amina Zoubeidi et al.
CLINICAL CANCER RESEARCH (2010)
Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study
Denis C. Talbot et al.
CLINICAL CANCER RESEARCH (2010)
Apolipoprotein B synthesis inhibition: results from clinical trials
Maartje E. Visser et al.
CURRENT OPINION IN LIPIDOLOGY (2010)
Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy
Fatima Akdim et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2010)
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis et al.
NATURE (2010)
A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus
John DeVincenzo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer
Stephen Chia et al.
CLINICAL CANCER RESEARCH (2009)
Treatment of malignant gliomas with TGF-β2 antisense oligonucleotides
Peter Hau et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses
Gail M. Gauvreau et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV)
John DeVincenzo et al.
ANTIVIRAL RESEARCH (2008)
A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer
Kim N. Chi et al.
CLINICAL CANCER RESEARCH (2008)
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia
Rebecca B. Klisovic et al.
CLINICAL CANCER RESEARCH (2008)
Antisense inhibition of ICAM-1 expression as therapy provides insight into basic inflammatory pathways through early experiences in IBD
Jessica R. Philpott et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma
Walter M. Stadler et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Phase I trial of g3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: A Children's Oncology Group study
Susan R. Rheingold et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo
Jeremy D. Heidel et al.
CLINICAL CANCER RESEARCH (2007)
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B
John J. P. Kastelein et al.
CIRCULATION (2006)
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer
KN Chi et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Genomics: success or failure to deliver drug targets?
UAK Betz et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2005)
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: Pharmacokinetics, pharmacodynamics, and clinical activity
G Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Overview of ribonucleotide reductase inhibitors: An appealing target in anti-tumour therapy
NMFSA Cerqueira et al.
CURRENT MEDICINAL CHEMISTRY (2005)
eIF-4E expression and its role in malignancies and metastases
A De Benedetti et al.
ONCOGENE (2004)
An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis
P Miner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis
SJH van Deventer et al.
GUT (2004)
Innovation - Target discovery
MA Lindsay
NATURE REVIEWS DRUG DISCOVERY (2003)
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia
G Marcucci et al.
BLOOD (2003)
Target selection in drug discovery
J Knowles et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice
V Wacheck et al.
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2002)
Share Paper
